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Abstract
Mouse APOBEC3 (mA3) is a cytidine deaminase with antiviral activity. mA3 is linked to the Rfv3 virus resistance factor, a gene
responsible for recovery from infection by Friend murine leukemia virus, and mA3 allelic variants differ in their ability to
restrict mouse mammary tumor virus. We sequenced mA3 genes from 38 inbred strains and wild mouse species, and
compared the mouse sequence and predicted structure with human APOBEC3G (hA3G). An inserted sequence was
identified in the virus restrictive C57BL strain allele that disrupts a splice donor site. This insertion represents the long
terminal repeat of the xenotropic mouse gammaretrovirus, and was acquired in Eurasian mice that harbor xenotropic
retrovirus. This viral regulatory sequence does not alter splicing but is associated with elevated mA3 expression levels in
spleens of laboratory and wild-derived mice. Analysis of Mus mA3 coding sequences produced evidence of positive
selection and identified 10 codons with very high posterior probabilities of having evolved under positive selection. Six of
these codons lie in two clusters in the N-terminal catalytically active cytidine deaminase domain (CDA), and 5 of those 6
codons are polymorphic in Rfv3 virus restrictive and nonrestrictive mice and align with hA3G CDA codons that are critical for
deaminase activity. Homology models of mA3 indicate that the two selected codon clusters specify residues that are
opposite each other along the predicted CDA active site groove, and that one cluster corresponds to an hAPOBEC substrate
recognition loop. Substitutions at these clustered mA3 codons alter antiviral activity. This analysis suggests that mA3 has
been under positive selection throughout Mus evolution, and identified an inserted retroviral regulatory sequence
associated with enhanced expression in virus resistant mice and specific residues that modulate antiviral activity.
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Introduction
Species susceptible to infectious retroviruses have evolved
numerous constitutively expressed antiviral factors that target
various stages of the retroviral life cycle. The factors responsible
for this intrinsic immunity include 3 that act at post-entry stages of
virus replication: Fv1, APOBEC3 and TRIM5a. Fv1 was discovered
in mice, [1] and only mice carry Fv1 [2,3]. TRIM5a was initially
identified in primates as an anti-HIV-1 restriction factor [4,5], and
while mice carry TRIM5a related sequences [6], no mouse
orthologue with virus restriction activity has been identified. Active
APOBEC3 genes, on the other hand, are found in various species
including human and mouse, and mouse and human APOBEC3
have antiviral activity against multiple retroviruses [reviewed in 7].
The APOBEC3 editing enzyme is incorporated into budding
virions. During reverse transcription in subsequently infected cells,
the virion-associated APOBEC3 catalyzes C-to-U deamination,
resulting in G-to-A mutations in the viral DNA [8]. The increased
mutational load has a major impact on viral fitness, and there is
also some evidence that APOBEC3 antiviral activity is enhanced
by additional deamination-independent mechanisms that act
before proviral integration [9,10].
APOBEC3 was initially described in primates, and human
APOBEC3 paralogues responsible for resistance are present as a
cluster of 7 genes on chromosome 22, the most extensively studied
of which is APOBEC3G (hA3G). HIV-1 can avoid inhibition by
hA3G through the action of one of its viral accessory proteins, Vif
(viral infectivity factor), that prevents incorporation of hA3G into
the virion [11]. The antiviral activity of hA3G can be observed
with Vif-negative HIV-1 and SIV lentiviruses as well as other
retroviruses such as equine infectious anemia virus (EIAV) and
mouse leukemia viruses (MLVs). In the mouse, there is only a
single APOBEC3 copy (mA3) on chromosome 15. Several
observations indicate that mA3 functions in antiviral defense:
mA3 inhibits infection by several viruses including HIV-1 and
mouse retroviruses such as mouse mammary tumor virus
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retroviruses [12–14]; mA3 knockout mice are more susceptible to
MMTV infection and tumorigenesis [15]; endogenous retroviruses
(ERVs) of MLV in the sequenced Mus genome show modifications
consistent with APOBEC3 activity [16].
Two recent studies proposed that mA3 is responsible for the
Friend virus resistance factor Rfv3 [10,17]. Rfv3 is one of several
host resistance factors that, like Fv1, were discovered in studies
with the pathogenic Friend MLV (FrMLV) [18]. Rfv3 was
identified as a non-major histocompatibility complex gene that
influences the duration of viremia, partly through its effects on the
production of virus-neutralizing antibodies [19]. The prototype
Rfv3 virus restrictive strain is C57BL, and BALB/c is the prototype
non-restrictive strain. The Rfv3 gene map location on chromosome
15 [20] has now been linked to the locus of Apobec3 [10,17]. That
mA3 is responsible for Rfv3 resistance is supported by the
observations that mA3 of C57BL restricts FrMLV replication
and FrMLV-induced disease more effectively than BALB/c mA3,
and that genetic inactivation of mA3 generates an FrMLV
susceptible phenotype [10,17]. It has also been shown that the
C57BL mA3 allelic variant is more effective than the BALB/c
allele in restricting MMTV [21].
The mA3 genes in prototype Rfv3 restrictive and nonrestrictive
strains differ in protein sequence, splicing pattern, and expression
level, and all three of these factors may contribute to resistance
[10,17,21]. Few strains and Mus species have been characterized
for these differences [21], so we sequenced mA3 genes from
various inbred strains and wild mice representative of the major
taxonomic groups of Mus. In this paper, we demonstrate that an
MLV long terminal repeat (LTR) disrupts a splice donor site in the
mA3 of C57BL and other strains and species and is associated with
altered expression levels, we demonstrate strong positive selection
of this gene in Mus that involves sites that distinguish the mA3
genes of Rfv3 virus resistant and susceptible mice, we use
homology modeling to position the positively selected residues in
two clusters on opposite sides of the putative active site groove, and
we describe the antiviral activity of mA3 genes carrying mutations
at these sites.
Results
Analysis of Mus musculus subspecies and inbred strains
for Apobec3 variants
Analysis of the antiviral activities of chimeric and wild type
C57BL and BALB/c mA3s by Takeda and colleagues [10]
indicated that the mA3 anti-FrMLV activity resides in the N-
terminal half of the C57BL protein. This 194 amino acid residue
segment contains the active Z2-type cytidine deaminase region
(CDA) [22,23], and the translated protein sequences of restrictive
C57BL and nonrestrictive BALB/c prototypes differ from one
another in this region at nine residues [10]. To determine the
distribution of the restrictive variant among mice and to identify
novel variants, we sequenced segments of mA3 containing these 9
residues from inbred strains and wild-derived mice representing
different taxa and/or mice trapped in different geographic
locations (Table S1)(Figure 1A).
In the course of this analysis, we identified a 531 bp sequence
inserted into the intron of mA3 of some laboratory strains between
exons 2 and 3 (Figure 1A,1B). The insertion was sequenced and
identified as an intact retroviral LTR (Figure 1C). This LTR is
96.6% identical to the LTR of the xenotropic gammaretrovirus
(X-MLV) NZB-IU-6, an MLV isolated from NZB strain mice
[24,25]. The mA3 LTR insert shows the expected direct repeats
characteristic of retroviral insertions, CAT and TATA boxes, and
a comparable enhancer region. The LTR is inserted in an
antisense orientation, and the site of insertion is the splice donor
site at the end of exon 2 (Figure 1D). Part of the splice donor site
contributes to the direct repeat flanking the insertion. The
insertion alters the last base of the splice donor site, a position
that is not highly constrained in the consensus sequence.
We screened 32 laboratory mouse strains for presence of this
LTR insertion by PCR (Figure 2). The insertion was identified in 6
strains, including C57BL and the 3 related strains NZB, NZL and
NZO. The LTR was absent from other NZB-related strains, from
other strains in the C57/C58 series and was also absent from 21
strains from other families of inbred strains. The sequences of
exons 2–4 of 13 strains were compared, and the only strains
identified as having the C57BL/6 coding sequence, NZB and RF,
also carried the LTR insertion. (Figure 2).
The common inbred strains of mice are a mosaic of Eastern
European M. m. musculus, Western European M. m. domesticus and
Asian M. m. castaneus [26,27]. Therefore we looked for the
sequence polymorphisms associated with the C57BL allele and for
the MLV LTR in M. musculus subspecies from breeding stocks
established from mice trapped in Old World sites where these
commensal (house mouse) subspecies originated, and from M.
musculus mice trapped in the Americas where they had been
introduced from Europe and Asia (Figure 2). Two wild-derived
mice from the Delmarva (Delaware-Maryland-Virginia) Peninsula,
CL and LEWES, had this LTR along with the C57BL mA3
coding sequence. PCR fragments diagnostic of the LTR insert
were also found in other Maryland mice as well as in two mice
trapped in California, one of three M. m. castaneus breeding lines,
and three of four lines developed from mice trapped in the former
Czechoslovakia. The LTRs sequenced in 4 laboratory strains and
5 wild-derived mice were 99% identical to one another, and the
mA3 genes of the LTR+ wild mice had several substitutions
compared to the C57BL gene. Thus, the LTR was acquired in
Eurasian species, and these LTR modified mA3 genes continued
to accumulate mutations after this insertion event.
Previous reports had determined that mA3 mRNAs can lack
exon 5 [10,13,14], and that BALB/c mA3 can also lack exon 2
[10]. We examined 31 mA3 mRNAs from cultured cells or tissues
Author Summary
APOBEC3 (mA3) is a cytidine deaminase with antiretroviral
activity. Genetic variants of mA3 are associated with the
restriction factor Rfv3 (recovery from Friend leukemia virus)
and with resistance to mouse mammary tumor virus. We
sequenced mA3 from laboratory strains and wild mouse
species to examine its evolution. We discovered that the
mA3 allele in virus resistant mice is disrupted by insertion
of the regulatory sequences of a mouse leukemia virus,
and this insertion is associated with enhanced mA3
expression. We also subjected the Mus mA3 protein
coding sequences to statistical analysis to determine if
specific sites are subject to strong positive selection, that
is, show an increased number of amino acid replacement
mutations. We identified 10 such sites, most of which
distinguish the mA3 genes of Rfv3 virus restrictive and
nonrestrictive mice. Six of these sites are in two clusters
that, in human APOBEC3G, are important for function. We
generated a structural model of mA3, positioned these
clusters opposite each other along the putative mA3 active
site groove, and demonstrated that substitutions at these
sites alter antiviral activity. Thus, mA3 has been involved in
genetic conflicts throughout mouse evolution, and we
identify an inserted regulatory sequence and two codon
clusters that contribute to mA3 antiviral function.
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PLoS Pathogens | www.plospathogens.org 2 July 2010 | Volume 6 | Issue 7 | e1000974Figure 1. Genomic structure of mA3. A) Schematic representation of mA3. The nine exons are indicated by black boxes and the black arrows
indicate the positions of the 7 PCR primers. The red arrow shows the position of the MLV LTR. B) PCR products of the indicated strains following
amplification with primers a and b. C) The sequences of the 531 bp mA3 C57BL intron insertion and the LTR of the NZB-IU-6 X-MLV (GenBank
No. K02730) were aligned using ClustalW [62] and marked to indicate the positions of the boundaries of the U3, R, and U5 regions and the CAT and
TATA boxes. Asterisks indicate identical bases in the two sequences. D) Position of the inserted LTR in mA3. The insertion is present in C57BL and
absent from BALB/c mice. A box encloses the splice donor site at the end of exon 2. The direct repeats flanking the LTR insertion are underlined and
the LTR sequence is in red.
doi:10.1371/journal.ppat.1000974.g001
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these splice variants by RT-PCR (Figure 3). mA3 mRNAs isolated
from different tissues of the same mouse produced the same
pattern of PCR products. Eleven of these 24 mice carry the LTR
(Figure 3B), and all 11 mice produced a single PCR product of the
size expected for a spliced message lacking exon 5 (Figure 3A).
Among the 13 LTR-free mice, two, M. m. molossinus and the
LTR2 inbred MOLD/RkJ line of this subspecies, produced this
same single isoform, while the other 11 LTR2 mice additionally
produced an exon5+ message that in 10 mice was significantly
more abundant than the Dexon5 isoform (Figure 3A). Both
sequenced BALB 3T3 mA3s lacked exons 2 and 5, and a third
barely detectable smaller PCR product was observed in BALB
3T3 and other LTR2 mice of the size consistent with the absence
of exons 2 and 5 (Figure 3A). The distribution of the MLV LTR
among these mice suggests that the LTR was inserted into the
mA3 variant that produces the Dexon5 isoform.
Previous reports had noted that mA3 expression level is
significantly higher in C57BL mouse tissues (LTR+) than in
BALB/c (LTR2) [10,21]. We isolated total RNA from the spleens
of 11 mice that had been typed for the LTR and for mA3 splicing
patterns. Included were mice from 2 breeding lines of M. m.
molossinus, the inbred MOLD/RkJ strain and a mouse from a
random bred colony, both of which are LTR2 and produce the
Dexon5 isoform (Figure 3B). Quantitative real-time PCR analysis
showed that the 7 LTR+ mice produced 4–20 fold higher levels of
mA3 mRNA than did the 4 LTR2 mice, including the two M. m.
molossinus mice (Figure 3C). These data demonstrate a correlation
between the LTR and expression level but not splicing pattern.
Selection analysis of mA3
We used sequenced segments of mA3 from 4 inbred strains and
21 wild-derived mouse species and subspecies for phylogenetic
analysis. The sequences were used to construct phylogenies, and
Figure 2. Distribution of the X-MLV LTR in inbred strains and wild-derived M. musculus house mouse species. An asterisk marks samples
that were sequenced, and those examined for splice variants are underlined. Mice found to carry the virus restrictive C57BL mA3 sequence are
bolded. CZECHI/CzI, CZECHII/CzII and LEWES/LW mice were sampled twice, from DNAs extracted from mice obtained from M. Potter in 1984, and
from The Jackson Laboratory DNAs isolated from inbred lines developed from the same colonies. M. musculus mice trapped in California (CalWM) are
listed without subspecies designation. Numbers in parentheses are the number of individuals tested. These 11 CalWM include mice trapped in
Bouquet Canyon, Lake Casitas, and the SC-1 cell line.
doi:10.1371/journal.ppat.1000974.g002
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of adaptive evolution and to identify possible sites of positive
selection. Two sets of DNA sequences were analyzed separately:
exons 2–4 amplified from genomic DNA or RNA and a set of 8
near full length DNAs generated by RT-PCR (Text S1, S2). The
sequences in the smaller dataset of 8 DNAs do not include the
extreme 59 and 39ends of the gene or exon 5 which was absent
from all but 3 of the 8 sequenced mRNAs.
The sequences were used to construct neighbor-joining trees
(based on Kimura 2-parameter distances) for the near full-length
sequences (Figure S1A) and for the 2–4 exon set (Figure 4A).
Modifications to the trees were made based on generally accepted
phylogenetic trees [29,30]. The data-based and taxonomy-based
trees were both used for PAML analysis and produced nearly
identical statistics (Tables S2,S3). Values of dN/dS along each tree
branch were calculated using the free-ratio model of PAML. A
dN/dS value .1 suggests that positive selection has acted along
that lineage. Several branches of the trees show evidence of
positive selection with dN/dS.1, or, when dS=0, by the
identification of 4 or more replacement substitutions.
Likelihood ratio tests indicate that mA3 has a significant
probability of having experienced positive selection, and this was
the case for all codon frequency models, and for both datasets
(Figures 4B and S1B, Tables S2, S3). The Bayes empirical Bayes
calculation of posterior probabilities in PAML identified specific
mA3 codon positions as having significant probability of positive
selection. In the separate analyses of the two datasets, we identified
20 codons as being under positive selection with high posterior
probability P.0.95, and 10 of these 20 codons were under very
strong positive selection with P.0.99 (Tables 1, S2, S3). Sixteen of
these 20 codons are in exons 2–4. Analysis of the smaller set of 8
near full-length genes identified a subset of the positively selected
codons identified by analysis of exons 2–4. The full-length
sequence analysis also identified 5 additional codons under
positive selection with P.0.95 that were not identified in the
exon 2–4 analysis: one codon, 142, in exon 3 of the active CDA
and four codons, 201, 273, 316 and 371, in the inactive C-terminal
CDA (Tables 1, S3).
There are 15 mA3 codons that specify different amino acids in
virus restrictive C57BL and sensitive BALB/c mice. Eleven of
these codons were found to be under positive selection (P.0.95),
and 5 of the codons under very strong positive selection (P.0.99)
mapped to two clusters in the active CDA (Figure 5). Because this
type of analysis is designed to identify sites involved in diversifying
selection (antagonistic interactions with pathogens being a prime
example), our results indicate that most of the residues that
distinguish C57BL and BALB/c mice identify key sites likely to be
involved in genetic conflicts. These results also suggest that mA3
has had a defensive role that predates development of the
laboratory strains and involves species in all 4 Mus subgenera.
Homology modeling
Homology models for the C57BL N-terminal active CDA
sequences were chosen from the LOMETS homology modeling
program based on templates that had the highest sequence
identity. The search identified several templates with highest
confidence, crystal structures determined for the catalytic domain
of hA3G (PDB ID 3IR2) [31] and (PDB ID 3IQS, 3E1U) [32].
The hA3G-3IR2 template model, based on the active hA3G C-
terminal Z1 deaminase domain, was chosen for detailed analysis
because it provides more coverage of the N-terminal Z2 domain of
the mouse sequence [23,31], and because it was the top LOMETS
solution overall.
The C57BL mA3 CDA sequence has 36.4% identity to the
hA3G CDA (Figure 6A). Superposition of the hA3G-3IR2 crystal
structure and the mouse homology model show they share the 5
stranded b-sheet core surrounded by 6 a-helices that is common to
known deaminase structures, along with a conservation of active-
site loops involved in substrate binding (Figure 6B). The sidechain
conformations of the C57BL residues involved in coordinating Zn
are identical to their counterparts in the hA3G structure
(Figure 6A,6B). The overall fold between the human and mouse
structures is nearly the same with the RMSD (root mean square
deviation) between backbone atoms of the C57BL mA3 model and
the human structure being 0.56A ˚. The RMSD between all atoms
for the mouse model and the human structure is 0.94A ˚.
Mutagenesis, NMR DNA titration data and structural analysis
of hA3G-3E1U and the NMR structure hA3G-2JYW have
identified key residues important in deaminase activity and
formation of the substrate groove [32–34]. Among these key
hA3G sites are the catalytic E259, 3 hydrophobic residues and 10
critical residues of which 9 are charged, all of which are within and
brimming the groove and all of which are needed for deaminase
activity (Figure 6A). N244 and R256 are associated with active
center loop 3 (AC loop 3), R213 and R215 are present in active
center loop 1 (AC loop 1), residue R313 resides on the floor of the
groove and D316, D317, R320 face the substrate groove at or near
the end of helix 4. The most obvious difference between hA3G-
3IR2 and the mouse model in these functionally important sites is
the presence of an 8 residue deletion in the AC loop 3 of the
mouse model. hA3G AC loop 3 is an unstructured loop, and the
deletion of the majority of the residues in the mouse AC loop 3
suggests they play no critical role; the mouse AC loop 3 structure,
however, does conserve the two residues found at the hA3G loop
base, N244 and R256, known to be critical for deamination [32],
and it is likely that these mouse residues, N66 and I70, serve
similar functions in mA3.
In contrast to this difference in AC loop 3, the functionally
important AC loop 1 and helix 4 residues in hA3G are retained in
mA3, and closely align with the two clusters of residues in mA3
shown here to be under positive selection (Figure 6A, 6B, 6C). On
the other side of the substrate groove from selected AC loop 1
residues 34–38 is the region encompassing residues 134–139 in
C57BL (and the corresponding region in hA3G); these residues are
at the end of helix 4 with some residues participating in the a-helix
and the rest as a loop. A solvent accessible surface representation
of the mA3 structure indicates the position of the predicted
substrate groove, and suggests the location of the two clusters of
positively selected residues on opposite sides of this substrate
groove (Figure 6D). The residues at the end of helix 4 and the
residues in the 34–38 cluster on the other side of the mA3 groove
likely serve steric roles in maintaining groove structure and likely
Figure 3. mA3 splicing patterns and expression levels in mouse strains and M. musculus subspecies. A) RT-PCR products from the
indicated sources using primers a and g. B) Splicing patterns observed in mRNAs of mice carrying LTR+ and LTR2 mA3 alleles. Mice listed as having
‘‘other patterns’’ produce the exon5+ isoform with one or more smaller mRNAs. The dotted lines separate common laboratory strains and wild-
derived mice. The tissue or cell source of RNA is indicated in {}. C) Quantitative real time PCR of mA3 transcripts in spleens of LTR+ and LTR2
laboratory and wild-derived mouse strains. Amplification levels were normalized to b-actin. The mice producing the exon5+ isoform are indicated at
the bottom. Sequence analysis of NFS/N and AKR mA3 indicates they carry the BALB/c allele.
doi:10.1371/journal.ppat.1000974.g003
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that govern substrate interactions.
In vitro antiviral activity of mA3 mutants
293T cells were cotransfected with the pLRB302 Friend virus
clone and mA3 clones to assess the relative antiviral activities of 4
mA3 clones: the wild type Rfv3 virus resistant C57BL mA3 [13]
and three clones with mutations that introduced residues of the
Rfv3 virus sensitive BALB/c: M1 (G34R, K37I, G38D), M2
(V134I, Q135R, T139N), M3 (all 6 substitutions) (Figure 7). Cells
and virus-containing supernatants were harvested 48 hours after
transfection. Cells were analyzed by immunoblotting for mA3
expression, and infectious virus in the supernatants was quanti-
tated by the XC overlay test. For each of the transfected mA3
clones, infectious virus titers decreased in a dose dependent
manner relative to increasing expression of mA3 (data not shown).
The wild type C57BL mA3 and the BALB-like M3 mutant both
showed antiviral activity, but the antiviral activity of M3 was
reduced relative to wild type mA3 (Figure 7). The M1 mutant
mA3 was found to reduce the infectivity of Friend virus as
effectively as wild type C57BL mA3, whereas M2 more closely
resembled M3 in antiviral activity suggesting that substitutions in
the 134–139 cluster are particularly important for anti-FrMLV
activity.
Discussion
This analysis indicates that mA3 has been involved in genetic
conflicts through Mus evolution. This gene shows strong positive
selection marked by an increase in replacement versus synony-
mous substitutions. Six of the 10 codons that evolved under
strongest positive selection are in two clusters in the N-terminal
catalytically active CDA. Five of these 6 codons specify different
amino acids in MLV and MMTV restrictive and nonrestrictive
mouse strains, and mutational analysis suggests these residues
contribute to antiviral activity. We also demonstrate that the
antiviral allelic variant has acquired a retroviral LTR insertion, the
presence of which is associated with elevated mA3 expression
levels in the spleens of inbred and wild-derived mice.
Retroviral insertions can be important functional components of
the host genome, and can clearly affect host gene expression.
Examination of spontaneous mutations in the mouse suggested
that 10–12% of all mutations are due to ERV insertions [35]. Like
the mA3 LTR, most of these mutant-associated ERVs are in
reverse orientation in introns, and the responsible mutational
mechanisms include two of relevance here: aberrant splicing and
enhanced transcription driven by the ERV LTR. While the mA3
LTR is inserted at a splice donor site, it does not alter splicing of
the associated intron, and although all mice carrying this LTR
produce the same Dexon5 mA3 isoform, the absence of this LTR
in at least one mouse species producing that isoform (M. m.
molossinus) suggests that the LTR was acquired by mice already
preferentially producing this splice variant. As for LTR-driven
altered expression levels, two of three previous studies that
compared mA3 RNA levels in virus-resistant and susceptible
strains reported that mA3 expression levels are significantly higher
in mice carrying the LTR+ C57BL allele compared to LTR2
BALB/c [21,17,10]. Our analysis of mA3 expression levels shows
a correlation between the presence of the LTR and elevated
expression in a variety of inbred strains and mouse species.
Because enhancer activation of cellular genes by viral LTRs can
Figure 4. Positive selection on exons 2–4 of mA3 in Mus. A) Cladogram showing branch values of dN/dS calculated using the free-ratio model
of PAML, with the number of replacement and synonymous changes in parentheses. When dS=0, dN/dS is infinite (Inf). dN/dS.1 suggests positive
selection along that lineage. Bootstrap support for this tree topology was generally good, with most bootstrap percentages .90%. The thin lines
represent branches with bootstrap values ,70%. Colors indicate Mus subgenera: brown, Coelomys; green, Pyromys; blue, Nannomys; red, Mus with
Mus house mouse (M. musculus) strains and species in pink. A purple arrow indicates insertion of the X-MLV LTR, and purple plus signs identify taxa
carrying the LTR. B) Likelihood ratio tests were used to test for positive selection. Neutral models (M1, M7) were compared with selection models (M2,
M8) using two different models of codon frequency (F3X4 or F61). P values ,0.0001 provide strong evidence of positive selection. Tree 1 is the data-
derived tree and tree 2 is the taxonomy-derived tree. Tree length is the average number of substitutions per codon along all branches. dN/dS ratio is
given for the codons under selection, along with the % of codons in this category.
doi:10.1371/journal.ppat.1000974.g004
Table 1. Sites that distinguish the mA3 genes in virus-
restrictive C57BL and virus-nonrestrictive BALB/c mice, and
sites under positive selection.
Codon Residue
Posterior Probability of Positive
Selection
b
C57BL BALB/c
a
Exons 2–4
(25 mice)
Full length
(8 mice)
25 T 0.967 0.453
34 G R 0.998 0.954
37 K I 1.000 0.968
38 G D 1.000 0.999
60 H 0.991 0.684
112 I V 0.105 0.468
113 V L 0.966 0.974
128 S 0.946 0.950
134 V I 0.999 0.781
135 Q R 1.000 0.999
136 D 0.999 0.189
138 E 0.976 0.974
139 T N 0.980 0.952
142 N 0.589 0.974
175 R 0.976 0.880
181 R K 0.946 0.778
183 L 0.977 0.982
200 M V - 0.674
201 D H - 0.993
202 P L - 0.472
225 R G - 0.691
273 T I - 0.979
316 C - 0.971
371 R H - 0.993
aThe BALB/c residue is given where it differs from C57BL.
bCalculated using PAML for two sets of sequences. The probabilities were
determined using Codon Table model F61 and selection Model 8 on the
taxonomy-based trees. Sites under selection with probabilities .0.95 are in
bold, and strongly selected sites with P.0.99 are also underlined. Use of the
codon frequency model F3X4 identified selection with P.0.95 at codon 181
and with P.0.99 at codon 183 (Table S2).
doi:10.1371/journal.ppat.1000974.t001
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distance from the cellular promoter, it is thus possible that the
enhancer of this inserted LTR sequence drives the elevated
expression observed in the LTR+ mice. This elevated expression
in conjunction with altered splicing may together have contributed
to the evolution of the antiviral C57BL mA3. It has been suggested
that the Dexon5 isoform has enhanced antiviral activity due to its
resistance to the viral protease [36]; elevated expression of this
variant due to subsequent LTR insertion would further boost the
survival value of this factor.
It is particularly intriguing that this X-MLV LTR sequence is
found in NZB and CZECH mice and one breeding line of M. m.
castaneus. These mice are unusual among laboratory strains and
wild mice in that they harbor highly active X-MLV ERVs
producing infectious virus, and such active ERV expression
increases the likelihood of insertional mutagenesis. NZB mice are
characterized by lifelong viremia with X-MLVs [37]. M. m.
castaneus and CZECH mice are among wild mouse Eurasian
populations with highest copy number of X-MLV ERVs [38], and
we have isolated infectious X-MLV-related virus from both of
these wild mice [39,40]. If in fact the inserted MLV LTR causes
elevated mA3 expression, then this would provide another
instance of an ERV sequence that is co-opted by the virus-
infected host for an antiviral function, other examples in the mouse
being Fv1, Fv4, and Rmcf [41].
In addition to differences in splicing and expression levels, mA3
genes of virus resistant and sensitive mice differ in protein
sequence. Our phylogenetic analysis showed that most of these
polymorphic sites are under strong positive selection. The
alignment of these sites with functionally important residues in
the hA3G C-terminal active CDA suggests they serve similar roles
in the mouse and that therefore, this function has been important
during Mus evolution. That this evolutionarily important function
is related to mA3 deaminase activity is supported by the
observation that the great majority of these selected residues are
in the N-terminal half of mA3 which encodes the active Z2 CDA
[22] and that antiviral activity resides in the first 194 amino acids
(exons 1–4) [10]. In the predicted mA3 structure, these positively
selected residues are positioned in one of two loops assigned
functional importance in hA3G, AC loop 1 and a cluster of
residues facing AC loop 1 on the other side of the putative
substrate groove [32–34]. The charged and hydrophobic residues
in these regions are positioned to maintain structural integrity of
the groove and to interact with one another and the nucleic acid
substrate in a way that could contribute to substrate specificity.
Three positively selected residues, G34, K37 and G38, in the
mA3 AC loop 1 sequence KNLGYAKGRKD are most likely
responsible for providing conformational freedom (in the case of
the G34 and G38) and for interacting favorably with the
phosphate backbone (in the case of K37). The electrostatic
contributions of K37 along with K40 and D41 probably play an
important role in determining substrate affinity and specificity
while Y35 is in a position to stack with a nucleotide base. The
analogous sequence in hA3G is NNEPWVRGRHE (207–217)
with R213, H216 and E217 positioned to interact electrostatically
with a phosphate backbone and W211 able to stack with a
nucleotide base. R39 (mA3) and R215 (hA3G) are positioned
similarly in that the residue provides an elaborate H-bonding
network defining the shape of AC loop 1 [32].
Five positively selected residues (V134, Q135, D136, E138 and
T139) lie in a region that comprises the end of helix 4 and an
adjacent loop that define the side of the substrate binding groove
Figure 5. mA3 sites under positive selection in the N-terminal Z2 CDA. At the top is a diagram of the mA3 segment (exons 2–4) that
encodes the N-terminal CDA showing the locations of the 9 codons that differ in virus restrictive C57BL and virus nonrestrictive BALB/c mice. At the
bottom is a graph showing the posterior probability of positive selection at each codon based on an analysis of 26 mA3 sequences using codon
frequency model F3X4 and selection Model 8 on the data-based trees (Table S2). A red line marks P=0.95. The red arrows indicate the 7 codons that
are strongly positively selected (P.0.99); these include 5 of the 9 polymorphic codons (long arrows) and codons 136 and 183. Codon 138 is positively
selected at 0.99.P.0.95.
doi:10.1371/journal.ppat.1000974.g005
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PLoS Pathogens | www.plospathogens.org 9 July 2010 | Volume 6 | Issue 7 | e1000974Figure 6. Comparative sequence and structure of the active cytidine deaminase regions of hA3G and mA3. A) Sequence alignment of
the C57BL mA3 CDA (GenBank No. NM_030255) with that of hA3G (GenBank No. NM_021822), using CLUSTAL X [62]. Gray shading, identical
residues. Red letters, AC LOOP 1. Blue letters, AC LOOP 3. Blue lines, a-helices. Blue arrows, b-strands. Blue dots, residues associated with the hA3G
substrate groove that are important for deamination [32–34]. Green boxes, sites under positive selection in mA3. Red triangles, sites that are
polymorphic between BALB/c and C57BL. B) Superimposed structures of hA3G-3IR2 and the mA3 homology model. a-helices are numbered. AC loops
1 and 3 are indicated. The red ball is zinc. C) Homology model of mA3 showing the 3 AC loop 1 residues under positive selection (yellow), and the 5
residues under strong (P.0.95) and very strong (P.0.99) selection that are on the opposite side of the substrate groove (red). D) Surface
representation of mA3 showing the location of the predicted substrate groove (green line) and the two clusters of selected residues in blue and red.
doi:10.1371/journal.ppat.1000974.g006
Evolution of the Mouse Antiviral APOBEC3 Gene
PLoS Pathogens | www.plospathogens.org 10 July 2010 | Volume 6 | Issue 7 | e1000974opposite of AC loop 1 (mA3 sequence YNVQDPET). Close
inspection of this region in the mouse model reveals that the
sidechain of D136 is in a position to H-bond with T139
maintaining the helical nature of helix 4 despite the presence of
P137. This has the result of allowing Q135 to form the top-side of
the groove allowing V134, N133 and Y132 to form the side of the
groove with Y132 in position to stack with a nucleotide base. Y132
is invariant in our mouse sequences along with nearby W102
which defines the floor of the groove. The homologous segment of
human APOBECs has now been implicated in the distinctive
substrate preferences among AID/APOBEC family members
which target cytosine within different sequence motifs. A
recognition loop responsible for these preferences (hA3G sequence
IYDDQGRCQ) lies between the b4 strand and the a4 helix
(Figure 6A, residues 314–322) [42]. That this highly variable
region controls substrate preferences is also supported by
mutational analysis [32,43]. Alignment of the active CDAs of
hA3G and mA3 indicates that this loop overlaps the 134–139
cluster of positively selected residues in mA3. This suggests that
genetic conflicts between host and pathogen in this case produced
positive selection that may be driven, not by protein-protein
interactions, but by the interaction of mA3 and varying ssDNA
substrates, a suggestion that is also consistent with the finding that
the efficiency of substrate deamination is sensitive to ssDNA
secondary structure [44].
Mutational analysis of 6 codons in the two clusters under
positive selection showed that introduction of BALB/c residues,
particularly in the 134–139 cluster, reduced antiviral activity
against Friend MLV. Further studies may determine if the
differences associated with overexpressed mA3 in transiently
transfected cells have physiological relevance, and whether
substitutions at these sites similarly affect restriction of other
retroviruses. It has been reported that mA3 shows stronger
antiviral activity against HIV-1 than against MLV [45], suggesting
that the genetic conflicts responsible for positive selection during
Mus evolution may have resulted from interactions with pathogens
unrelated to the FrMLV used here.
Previous phylogenetic analysis of hA3G had identified 21 sites
under very strong positive selection, 9 of which are in the active
CDA [46]. One of these sites, R213, aligns with one of the clusters
of residues (positions 34–38) under strong selection in mA3;
however, the analysis of hA3G did not identify selection in the
region aligning with the second cluster under strong selection in
mA3 (positions 134–139), although this segment is a substrate
recognition loop that is highly variable among members of the
AID/APOBEC family [42]. The additional sites identified to be
under positive selection in the hA3G active CDA have no
positively selected counterparts in mA3. Among these additional
sites in hA3G, two, H248 and K249, lie in AC loop 3 [46].
Mutagenesis and analysis of hA3G structure have implicated this
loop in antiviral deamination [32], but much of AC loop 3 is
deleted in the mouse, leaving only the key residues at the base of
this loop that align with critical residues N244 and R256. The
residues at these sites are invariant in our mA3 sequences
suggesting their evolution is under purifying selection. The
differences in AC loop 3 between hA3G and mA3 and the fact
that different residues are under selection in hA3G and mA3
suggests there may be functional differences between these
proteins.
Our analysis of the full-length mA3 sequences also identified
four sites under positive selection in the C-terminal half of the
protein (Tables 1, S1) that carries the Z3 CDA that has been
determined to be inactive [22]. It is not clear what role these
residues serve. An antiviral role for the C-terminal half of mA3 is
suggested by the observation that that the conserved glutamates in
the N-terminal Z2 domain and the C-terminal Z3 domain of mA3
are both required for antiviral activity against HIV-1 [45]. Other
evidence suggests that the inactive CDA is involved in virus
encapsidation [47]. We note that alignment of the mouse Z2 and
Z3 CDA regions shows that one of the two selected Z3 codons,
P316, aligns with the 134–139 selected cluster of codons in Z2,
VQDPET. Another selected codon in the Z3 CDA, T273, aligns
with an hA3G segment with two codons under selection in
primates [46]. This suggests the possibility that this Z3 CDA may
have had deaminase activity in some branches of the Mus lineage.
Further analysis of the C57BL and BALB/c mA3 genes should
shed light on the functional roles of the polymorphic residues in
the two groove-associated clusters. The information from
additional phylogenetic, structural, and functional comparisons
will help describe the range of antiviral activity and evolutionary
history of this gene. We are currently analyzing additional mA3
mutants for antiviral activity, and using molecular dynamics
simulations to describe the structural implications of specific
substitutions.
Methods
Genomic DNA and RNA
DNA and RNA were isolated from animals and cell lines
developed from laboratory mouse strains and from wild mice and
wild mouse-derived breeding colonies (Table S1). Many wild-
derived mice were obtained from M. Potter (NCI, Bethesda, MD).
SAMP8 mice were provided by R. Carp (New York State Institute
Figure 7. Antiviral activity of mA3 mutants carrying BALB/c
residues at the 34–38 and 134–139 clusters. 293T cells were
cotransfected with Friend virus clone pLRB302 and the indicated mA3
variants. The experiment was repeated six times with some experi-
mental variations; shown are two representative experiments. One
experiment (left panel) used 3 mg of pLRB302 and 1 mg of mA3. The
second experiment (right panel) used 4 mg of pLRB302 and 0.5 mgo f
mA3, and total DNA amounts were adjusted to 6 mg with empty
pcDNA3.1(2) vector DNA; mA3 was reduced because titration
experiments showed 0.5 mg to have antiviral activity (not shown).
Infectivity of collected Friend virus was assayed by the XC overlay test
normalized against reverse transcriptase activity (experiment 1) or virus
capsid protein in pelleted virus (experiment 2). Infectivity of virus
produced in the absence of mA3 was defined as 100%, and infectivity of
the other viruses is given as a percentage of the control. Virus infectivity
was determined 6 times in both experiments.
doi:10.1371/journal.ppat.1000974.g007
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NY), SIM.S mice were obtained from E. Boyce (Memorial Sloan-
Kettering Cancer Center, NY), and mice trapped in California
were provided by S. Rasheed (University of Southern California,
Los Angeles). Mice or DNA samples of M. spretus (SPRET/EiJ), M.
m. castaneus (CAST/EiJ), various inbred lines derived from M. m.
molossinus, PERA, PERC, PWD, and the inbred strains listed in
Figure 2 were obtained from The Jackson Laboratory (Bar
Harbor, ME).
A set of African pygmy mouse DNA samples was obtained from
Y. Cole and P. D’Eustachio (Depts. Biochemistry and Medicine,
NYU, New York); these mice had been classed into 4 species of
subgenus Nannomys mice on the basis of skeletal features by J. T.
Marshall (Smithsonian Natural History Museum, Washington,
DC). A sample of M. m. macedonicus DNA was provided by R.
Elliott (Roswell Park, Buffalo). Cell lines used as DNA and RNA
sources included NZB-Q and M. fragilicauda cells obtained from J.
Hartley (NIAID, Bethesda, MD), cells from some wild mouse
species obtained from J. Rodgers (Baylor College of Medicine,
Houston, TX), and NIH 3T3, M. dunni [48], SC-1 [49], A9 (C3H/
He) [50], and CMT93 (C57BL) (ATCC CCL-223).
Ethics statement
All studies in which animals are involved were performed in
accordance with the guidelines of the Committee on the Care and
Use of Laboratory Animals under an NIAID-approved animal
study protocol [51], and all studies and procedures were reviewed
and approved by the Institutional Animal Care and Use
Committee of the NIH.
APOBEC3 sequences of wild mouse species
APOBEC3 segments were amplified from mouse genomic DNAs
or RNAs using primers designed from coding, flanking or intron
sequences based on the C57BL genomic sequence (GenBank
No. NT_03921) (Figure 1A). Exon 2 was amplified using forward
intron primer a: 59-CTCCTCTCCCTCTGTCTTCCT and
reverse primer b: 59-GGATTCAAGGTATGAGCCACCATGC.
Exons 3 and 4 were amplified using primer c: 59-GCTTCAA-
CAGGGCTCAGAGTGC and primer d: 59-AGGTTTGGGAG-
GAGGGAGAAC. Reverse transcription PCR (RT-PCR) was
used to amplify near full-length APOBEC3 from total RNA using
primer e in exon 1 (59-GGACCATTCTGTCTGGGATGCAGC-
CATCG) and primer f in exon 9 (59-GACATCGGGGGAC-
CAAGCTGTAGGTTTCC) and a shorter RT-PCR fragment
was generated using primer a and primer g (59-GGTT-
GTAAAACTGCGAGTAAAATTCC). The larger RT-PCR
product contained 1083 bp of the full-length 1287 bp mA3
sequence. Most of these products lacked the 99 bp exon 5, and
the aligned sequences lack 72 bp at the 59 end and 33 bp at the 39
end of the gene. PCR products were sequenced directly in
some cases, and in others fragments were first cloned into
pCR2.1-TOPO (Invitrogen, Carlsbad, CA) before sequencing
(Text S1, S2).
Real-time PCR
Total RNAs from mouse spleens were isolated using Trizol
(Invitrogen). Reverse transcription was carried out at 50uC for
1 hour using 2 mg of total RNA in the presence of Oligo (dT)
primer (Ambion, Austin, TX) and SuperScript III (Invitrogen).
After reverse transcription, the reaction mixtures were diluted to
1000 ml with DEPC-water. 1 ml of the diluted cDNA were added
to a 15 ml PCR reaction mix containing 0.4 mlo f1 0mM primers
and 26SYBR Green PCR mix (Applied Biosystems, Foster City,
CA ). APOBEC3 transcripts were amplified using primers 59-
GACCATTCTGTCTGGGATGCA and 59-TTCTAGTCACT-
TCATAGCACA. b-actin was also measured using primers (59-
GTGGGGCGCCCCAGGCACCA; 59- CTCCTTAATGTCAC-
GCACGATTTC) as a normalization control. Amplification was
done under the condition of 15 s at 95uC and 1 min at 60uC for
50 cycles in a 7300 Real Time PCR System (Applied Biosystems).
Antiviral activity of mA3 sequence variants in vitro
HA-tagged mA3 [13] was obtained from the NIH AIDS
Research and Reference Reagent Program (Germantown, MD)
(catalog no. 10021) and mutagenized using the QuikChange
mutagenesis kit (Stratagene, La Jolla, CA) to introduce substitu-
tions at 6 codons. M1 (G34R, K37I, G38D) was generated using
primer 59-CCACTTTAAGAACCTACGCTATGCCATTGATC-
GGAAAGATACCTTC and its reverse complement. M2
(V134I, Q135R, T139N) was generated using primer 59-
GCTCCCGCCTCTACAACATCCGAGACCCAGAAAATCAG-
CAGAATCTTTGC and its reverse complement. M3, containing
mutations at all 6 codons, was generated by mutating M1 with the
primers designed for M2. Mutations were confirmed by sequencing.
Attempts to generate stable transfectants of various mouse cells
expressing these mA3 variants were not successful. Human 293T
cells were co-transfected with 3–4 mg of the pLRB302 clone of
Friend MLV [52] obtained from L. Evans (RML, NIAID,
Hamilton, MT), and 0.5 or 1.0 mg mA3. At 48 hours after
transfection, the culture supernatant was collected and virus
infectivity was measured by the XC overlay test [53]. In this test,
subconfluent cultures of NIH 3T3 cells were infected with virus
dilutions, irradiated 4 days later and overlaid with rat XC cells.
Infectivity was determined as plaque-forming units per ml of culture
fluid. Infectivity was normalized against reverse transcriptase activity
[54] or virus-associated capsid protein in pelleted virus. After
electrophoresis on 12.5% SDS-polyacrylamide genes and transfer to
polyvinylidene difluoride membranes, capsid protein was detected
using polyclonal goat anti-Rauscher MLV p30 antiserum (Viromed
Biosafety Laboratories (NCI/BCB Repository), Camden, NJ) and
horseradish peroxidase conjugated rabbit anti-goat antibody (In-
vitrogen catalog # R21459). The transfected 293T cells were lysed
and tested for mA3 expression by western immunoblot analysis. Cell
lysates were subjected to electrophoresis and western blots were
probed with a monoclonal antibody against HA, HA-7 (Sigma
catalog #H-3663) and a monoclonal anti-tubulin antibody (Sigma
#T-9026).
Selection analysis of lineages and codons
DNA sequences were aligned using MUSCLE [55] and
improved manually. Two phylogenies were produced, one for
the full-length sequences and one for the exon 2–4 sequences. In
all cases the Kimura 2-parameter distance-based neighbor-joining
phylogenies for each set returned by PHYLIP (version 3.68) [56])
were corrected for closer correspondence to the consensus Mus
phylogeny [29,30]. The trees were corrected to make the Nannomys
species a monophyletic group and to place M. spretus basal to the
M. musculus node.
The codeml program of the PAML4 package [28] was used for
maximum likelihood analysis of codon evolution [57]. Both
lineage-specific and codon-specific analyses were performed. In
the lineage-specific selection analyses, the free ratio model (codon
model=1) was used to calculate branch-specific rates of dN/dS.
In this model each branch is assumed to have a specific dN/dS
ratio. The likelihood of the phylogeny under this model was tested
against the likelihood of the phylogeny under the model of one
uniform dN/dS ratio across all branches (codon model 0) using a
likelihood ratio test (LRT). The significance of the LRT value was
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freedom for the exon 2–4 sequence analysis and 12 degrees of
freedom for the full-length sequence analysis.
Selection acting on Apobec3 codons was analyzed using two models
of equilibrium codon frequencies and four models of codon selection.
The two codon frequency models used were the F3x4 model (codon
frequencies estimated from the nucleotide frequencies in the data at
each codon site) and the F61 (Codon Table) model (frequencies of
each of the 61 non-stop codons estimated from the data). The codon
selection models were two neutral/negative selection models(M1 and
M7) which were compared against corresponding positive selection
models which included a category for dN/dS.1( M 2a n dM 8 ,
respectively). The significance of this additional codon selection
category was assessed using LRTs of the phylogeny likelihoods under
t h en e u t r a la n dp o s i t i v es e l e c t i o nm o d e l s .S i g n i f i c a n c eo ft h et e s t
statistics was calculated using a chi-squared distribution with two
degrees of freedom. The Bayes empirical Bayes algorithm [58] was
used to calculate the posterior probability of individual codons
experiencing dN/dS.1.
Homology modeling
The C57BL mouse mA3 sequence (GenBank No. NM_030255)
was submitted to the LOMETS program [59]. A model
constructed using a template with the highest sequence identity
was chosen from the top ten solutions ranked by a combination of
highest sequence identity, most coverage, Z-score and overall
confidence. The model was generated using Modeller v4 [60] and
energy optimized in SYBYL7.3 using the AMBER7 ff99 forcefield
with AMBER7 ff99 atom types and charges with the Powell
method to a termination gradient of 0.05 kcal/mol?A ˚. The model
was examined using Procheck [61] to detect any bad geometries.
Accession numbers
mA3 exon 2–4 sequences were given GenBank Accession
Nos. GQ901957–GQ901974. Near full length sequences were
given GenBank Nos. GQ871500–506.
Supporting Information
Table S1 Designations and sources of wild-derived mice, cells
and DNAs.
Found at: doi:10.1371/journal.ppat.1000974.s001 (0.08 MB
DOC)
Table S2 PAML summary results for mA3 exons 2–4.
Found at: doi:10.1371/journal.ppat.1000974.s002 (0.10 MB
DOC)
Table S3 PAML summary results for Apobec3 full-length
sequence.
Found at: doi:10.1371/journal.ppat.1000974.s003 (0.10 MB
DOC)
Figure S1 Phylogenetic tree and likelihood ratio tests for the
mA3 full length sequence. A) Data-derived cladogram showing
branch values of dN/dS calculated using the free-ratio model of
PAML, with the number of replacement and synonymous changes
in parentheses. When dS=0, dN/dS is infinite (Inf). dN/dS.1
suggests positive selection along that lineage. B) Likelihood ratio
tests were used to tests for positive selection. Neutral models (M1,
M7) were compared with selection models (M2, M8) using two
different models of codon frequency (F3X4 or F61). P values
,0.0001 provide strong evidence of positive selection. Tree 1 is
the data-derived tree and tree 2 is the taxonomy-derived tree. Tree
length is the average number of substitutions per codon along all
branches. dN/dS ratio is given for the codons under selection,
along with the % of codons in this category.
Found at: doi:10.1371/journal.ppat.1000974.s004 (0.47 MB TIF)
Text S1 Alignment of full-length mA3 sequences from mice
listed in Table S1. The codons under positive selection by PAML
are boxed, with red boxes indicating codons under very strong
selection (P..99). Green fill marks codons that distinguish C57BL
and BALB/c. Selection analysis by maximum likelihood is limited
to sites typed in all DNAs and excludes 72 bp at the 59 end, 33 bp
at the 39 end and the 99 bp exon 5. The C57BL mA3 sequence
was from GenBank (No. NM_030255). The sequence derived
from NIH 3T3 was used in place of BALB/c as all clones from
BALB 3T3 cells lacked exons 2 and 5, and the NIH 3T3 sequence
was otherwise identical to the published BALB/c sequence
(GenBank No. EDL04624).
Found at: doi:10.1371/journal.ppat.1000974.s005 (0.07 MB
DOC)
Text S2 Alignment of mA3 Exon 2–4 sequences from mice listed
in Table S1. The codons under positive selection by PAML are
boxed, with red boxes indicating codons under very strong
selection (P..99). Green fill marks codons that distinguish C57BL
and BALB/c. The C57BL mA3 sequence was from GenBank
(No. NM_030255). BALB/c exons 3 and 4 were amplified from
mRNA and exon 2 from DNA.
Found at: doi:10.1371/journal.ppat.1000974.s006 (0.08 MB
DOC)
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